Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes

Sulaiman Yusuf; Heru Noviat Herdata; Eka Destianti Edward; Khairunnisa Khairunnisa

doi:10.12688/f1000research.128810.2

Home Browse Comparison of oral iron chelators in the management of transfusion-dependent...

ALL Metrics

Views

Downloads

Get PDF

Get XML

Export

▬

✚

Brief Report

Revised

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes

[version 2; peer review: 2 approved]

Sulaiman Yusuf ¹, Heru Noviat Herdata², Eka Destianti Edward², Khairunnisa Khairunnisa³

PUBLISHED 19 Dec 2023

Author details Author details

¹ Division of Gastroenterohepatology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia
² Division of Hematology-Oncology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 32111, Indonesia
³ Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia

Sulaiman Yusuf
Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Heru Noviat Herdata
Roles: Formal Analysis, Investigation, Methodology, Resources, Validation, Writing – Review & Editing

Eka Destianti Edward
Roles: Data Curation, Formal Analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – Review & Editing

Khairunnisa Khairunnisa
Roles: Investigation, Resources, Supervision, Validation, Visualization, Writing – Review & Editing

OPEN PEER REVIEW

REVIEWER STATUS

Abstract

Background

Excess iron deriving from a chronic transfusion and dietary intake increases the risk for cardiac complications in β-thalassemia major patients. Deferiprone and deferasirox are commonly prescribed to thalassemic patients who are at risk of iron overload. This study aimed to compare the performance and toxicity of deferiprone and deferasirox in β-thalassemia major patients.

Methods

A cross-sectional observation was performed on 102 patients with β-thalassemia major. Serum ferritin along with total, indirect, and direct bilirubin levels were measured. Levels of liver enzymes, transaminase (ALT), and aspartate transaminase (AST), were also determined. Ferritin correlations with serum ALT, AST, and total bilirubin were constructed based on Spearman’s rank correlation. Statistical differences based on the serum parameters were analyzed between deferiprone and deferasirox groups. The differences of iron chelators’ effects between those receiving short-term (≤7 years) and long-term (>7 years) blood transfusion were also analyzed.

Results

The averaged levels of bilirubin, ALT, AST, and ferritin were found to be high. Ferritin was positively correlated with ALT (r=0.508 and p<0.001) and AST ((r=0.569; p<0.001). There was no statistical difference in ferritin levels between the deferiprone and deferasirox groups (p=0.776). However, higher total bilirubin and ALT were observed in the deferasirox group than in the deferiprone group (p=0.001 and 0.022, respectively). Total (p<0.001), indirect (p<0.001), and direct bilirubin levels (p=0.015) were significantly higher in patients with long-term transfusions than those receiving short-term transfusions. Higher ferritin was found with a statistical significance of p=0.008 in the long-term transfusions group.

Conclusions

Ferritin is high in people with transfusion-dependent β-thalassemia major and positively correlated with ALT and AST. Deferasirox might pose a higher risk of developing hepatic injury as compared with deferiprone. Yet, no significant change of deferasirox efficacy (based on ferritin level) was found between those receiving short-term and long-term transfusions.

Keywords

Alanine transaminase, aspartate transaminase, iron overload, deferiprone, deferasirox

Corresponding author: Sulaiman Yusuf

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2023 Yusuf S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite: Yusuf S, Herdata HN, Edward ED and Khairunnisa K. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]. F1000Research 2023, 12:154 (https://doi.org/10.12688/f1000research.128810.2) First published: 10 Feb 2023, 12:154 (https://doi.org/10.12688/f1000research.128810.1) Latest published: 19 Dec 2023, 12:154 (https://doi.org/10.12688/f1000research.128810.2)

Revised Amendments from Version 1

In this new version, we have re-stressed the aim of the study at the end of the Introduction. The data of Thalassemia from Indonesia, the dosage of the iron chelation used in the study has been added in the revised article. We have added the approach to exclude the possibility of inflammatory state among the patients. The dosage of the iron chelation used in the study has been added. In addition, the height data have been changed to meter unit. More discussion has been added in particular the difference between the two types of oral chelating drugs (deferiprone and deferasirox).

See the authors' detailed response to the review by Pustika Amalia Wahidiyat
See the authors' detailed response to the review by Ahmed Yahya Dallal Bashi

Introduction

Though the disease was known to be centered around the Southeast Asian and Middle Eastern regions, a recent review has highlighted the increasing prevalence of β-thalassemia in North America and Western Europe.¹ Approximately 1.5% of the world’s population are carriers of β-thalassemia, where the number varied across regions, including in specific countries.² For example, among Southeast Asian countries the number of β-thalassemia carriers ranged between 0.5% and 12.8% as reported in Myanmar and Malaysia, respectively.³ In Indonesia, it is estimated that 3.0–10.0% of the population have the β-thalassemia trait depending on the population.⁴ In 2019, data from Indonesian Pediatric Association indicated at least there were 10,500 registered thalassemia patients but this figure is far below the estimation.⁴

People with β-thalassemia require a lifelong blood transfusion due to their inability to produce sufficient normal hemoglobin A. Ineffective erythropoiesis in β-thalassemia patients occurs because of the inherited genetic mutations causing impaired β-globin protein and consequently the imbalance in α- and β-globin chains production.⁵ The condition leads to the inevitable hyperabsorption of irons deriving from either dietary irons or those from blood transfusion.⁶ Excessive iron and its deposition could cause cardiac complications, which currently affects 25% of total 26,893 β-thalassemia major patients according to a meta-analysis.⁷ To prevent the toxicity of iron overload, the patients should receive iron chelating therapy. The life expectancy of people with β-thalassemia major could be improved, even to be similar to those with β-thalassemia intermedia if managed with an iron chelating agent.⁸

Based on a systematic literature review, a person with transfusion-dependent thalassemia should pay $128,062 for blood transfusion and iron chelating therapy.⁹ In Indonesia itself, the access to iron chelation therapy is still a challenge, especially in rural areas.¹⁰ It is worth mentioning that Indonesia lies in a thalassemia belt area owing to the high prevalence and carrier rate.¹¹ Therefore, it is of importance to focus the research on the Indonesian population to improve the clinical management and monitoring of iron overload among patients with β-thalassemia major. There are two oral iron chelating drugs usually used in Indonesia deferiprone and deferasirox. Deferiprone has two ligands which could coordinate with Fe forming a complex with three chelator molecules.¹² Meanwhile, deferasirox has three ligands that could coordinately bind one Fe atom to form a complex with two chelator molecules.¹² Understanding the performance of these two drugs in reducing the iron level could provide an insight into more effective and cost-efficient management. Although these drugs are the main oral iron chelating drugs in Indonesia,⁴ studies comparing their effects on liver function are limited and focused in Java.¹³^,¹⁴ In addition, the iron storage protein, ferritin, has been suggested as an indicator of iron overload and has been used to monitor iron chelation therapy efficacy.¹⁵^,¹⁶ Its correlation with liver enzymes could be an indicator for liver damage monitoring.¹⁷^,¹⁸

The objective of the study was to compare the performance and adverse effects of two oral iron chelating drugs (i.e., deferiprone (Ferriprox) and deferasirox (Exjade)) on the liver in β-thalassemia major patients with chronic transfusion. The effect on the liver were assessed by measuring the levels of serum ferritin, transaminase (ALT), aspartate transaminase (AST), total bilirubin, indirect bilirubin and direct bilirubin among patients with β-thalassemia major and chronic transfusion. In addition, we performed a correlation test between serum ferritin with ALT, AST, and total bilirubin.

Methods

Study design

This research was conducted prospectively on children (1 to 18 years old) with β-thalassemia major who were hospitalized at the Children’s Thalassemia Center at Dr. Zainoel Abidin Hospital in Banda Aceh within the February–March 2022 period. The research aimed to seek the correlation between the administration of the iron chelating agent deferiprone with aspartate aminotransferase (AST), alanine aminotransferase (ALT), ferritin, and albumin. Ethical clearance was provided by the Ethical Committee of Dr. Zainoel Abidin Hospital, Banda Aceh (013/EA/FK-RSUDZA/2022, KEPPKN No 1171012P). Written informed consent for all the patients’ participation was obtained from the patients’ guardians.

Patient recruitment

Diagnosis of β-thalassemia major was established based on hemoglobin (Hb) electrophoresis. The patient was included if having serum ferritin >1500 ng/mL, treated with oral Ferriprox^® (containing deferiprone with dose of 75 mg/kg body weight each day) or Exjade^® containing deferasirox with dose of 20 mg/kg body weight each day in single dose), and they were not prescribed with other iron chelation therapy (i.e., injectable deferoxamine) within the last three months. Patients having histories of hepatitis virus (HPV) B and HPV C were excluded. In addition, since the level of ferritin could be influenced by some conditions, all patients that had infection (assessed through physically and laboratory tests including routine lab, C-reactive protein level and procalcitonin) and autoimmune diseases were excluded.

Consecutive sampling was employed to select the study subjects with sampling size calculated based on Equation 1.

n = \frac{(Zα + Zβ)}{0.5 Ln (\frac{1 + r}{1 - r})} + 3

where,

α: Type I error at 5%

Zα: Standard alpha (1.64)

Β: Type II error at 10%

Zβ: Standard beta (1.28)

r: minimally significant correlation coefficient at 0.5.

Data collection

Demographic characteristics data included in this study were sex, gender, and educational level, obtained by interviewing patients or their guardians. Nutritional status was calculated through anthropometric measurement from the patient’s body weight (kg) and height (m). The values obtained therein were categorized into obesity (>120%), overweight (>110–120%), healthy weight (90–110%), underweight (70–90%), and short stature (<70%).

Serum parameters analysis

Venous blood (10 mL) was drawn from each subject and analyzed for serum bilirubin, ferritin, AST, and ALT. Serum bilirubin was measured using direct diazo reaction. Serum ferritin level was obtained from an analysis using the immunoassay technique. Serum AST and ALT determinations were based on non-pyridoxal phosphate Inverse Fast Fourier Transform (IFFT).

Statistical analysis

Continuous data were presented as mean±standard deviation (SD). Normality of the data distribution was judged based on a Kolmogorov-Smirnov test. Depending on the normality test, the significant difference was statistically analyzed using independent t-test or Mann-Whitney U test. All statistical analyses were performed on SPSS version 22 (SPSS Inc., Chicago, IL, USA) (SPSS, RRID: SCR_019096).

Results

Characteristics of patients

The patients included in this study were a balanced number of males (50%) and females (50%) with <10 years old as the most predominant age, followed by 10–15 years old and >15 years old, respectively (Table 1). The average body weight and height of the patients were 25.56±9.75 kg and 1.25±0.18 m. As many as 45.1% of the total patients were in the healthy weight category, while another 45% were categorized as underweight. Almost all patients required 1 bag of blood each month. The average ferritin level of 3531.80±2322.44 ng/mL exceeded the normal range (7–140 ng/mL). The averaged total, indirect, and direct bilirubin levels were 1.86±1.00, 1.25±0.88, and 0.62±0.42 mg/dL, respectively. The averaged ALT and AST levels were also found to be higher than the upper limit for children (51.57±32.77 and 49.19±48.32, respectively). High SDs in ALT and AST indicate that there were some patients having these values in the normal range (10–40 UI/mL) but some were abnormal.

Table 1. Characteristics of the patients (n=102).

Variable	n (%)
Gender
Male	51 (50)
Female	51 (50)
Age
<10 years old	47 (46.1)
10-15 years old	41 (40.2)
>15 years old	14 (13.7)
Body weight, mean±SD (kg)	25.56±9.75
Height, mean±SD (m)	1.25±0.18
Nutritional status
Short stature	7 (6.8)
Underweight	45 (44.1)
Healthy weight	46 (45.1)
Overweight	2 (2)
Obesity	2 (2)
Blood bag required per month
>1 bag	3 (2.9)
1 bag	98 (96.1)
2 bags	1 (1)
Ferritin, mean±SD (ng/mL)	3531.80±2322.44
Total bilirubin, mean±SD (mg/dL)	1.86±1.00
Indirect bilirubin, mean±SD (mg/dL)	1.25±0.88
Direct bilirubin, mean±SD (mg/dL)	0.62±0.42
ALT, mean±SD (IU/L)	51.57±32.77
AST, mean±SD (IU/L)	49.19±48.32

Correlations between serum ferritin and liver enzymes

Correlation tests were performed to see if the ferritin level was correlated with ALT, AST, or total bilirubin, where the results have been presented in Table 2. Based on Spearman’s rank correlation analysis, serum ferritin was found to be positively correlated with serum ATL based on r=0.508 and p<0.001. Similarly, serum ferritin was also positively correlated with serum AST with a statistical significance (r=0.569; p<0.001). These correlations suggest the increase in serum ferritin level contributes to the increase in serum ALT and AST levels. No correlation was found between serum ferritin and total bilirubin.

Table 2. Correlation between ferritin and ALT, AST, or total bilirubin (n=102).

Variable	R	p-value
Ferritin – ALT	0.508	<0.001*
Ferritin – AST	0.569	<0.001*
Ferritin – total bilirubin	-0.067	0.451

* Statistically significant at p<0.01 based on Spearman’s rank correlation.

Comparisons between deferiprone and deferasirox

Comparisons of serum ferritin, bilirubin, ALT, and AST among patients receiving either deferiprone or deferasirox have been presented in Table 3. In this analysis, only 90 patients were included while 12 others were excluded because information about blood types was missing for some patients, or they had been treated with drug combinations. Levels of serum total, indirect, and direct bilirubin were found to be significantly different between the two groups (p<0.05). Higher levels of serum ALT and AST were found in the deferasirox group as compared with the deferiprone group, yet statistical significance was only achieved in terms of serum ALT level.

Table 3. Comparisons between deferiprone and deferasirox based on levels of serum ferritin, bilirubin, ALT, and AST (n=90).

Variable	Deferiprone (n=50) Mean±SD	Deferasirox (n=40) Mean±SD	Statistic	p-value
Ferritin (ng/dL)	4237.45±3185.01	3941.82±2477.69	1075.000	0.776
Total bilirubin (mg/dL)	1.46±0.67	2.16±1.13	675.500	0.001*
Indirect bilirubin (mg/dL)	0.93±0.50	1.50±1.04	681.500	0.001*
Direct bilirubin (mg/dL)	0.53±0.34	0.65±0.44	822.000	0.029*
ALT (IU/L)	47.66±29.23	60.14±34.71	807.500	0.022*
AST (IU/L)	47.87±51.01	54.10±39.62	921.500	0.151

* Statistically significant at p<0.05 using Mann-Whitney U test.

We further analyzed the differences in serum ferritin, bilirubin, ALT, and AST levels between patients receiving long-term and short-term transfusions. The data of this analysis have been presented in Table 4. Significantly higher serum ferritin level was observed in the group that had undergone long-term transfusion (p<0.05) among the deferiprone recipients. As in patients receiving deferasirox, long-term blood transfusion did not give a significant effect on ferritin levels. However, among those receiving deferasirox, long-term blood transfusion yielded significantly higher serum total, indirect, and direct bilirubin levels. Neither deferiprone nor deferasirox prescription yielded statistically different effects on serum ALT and AST levels between those undergoing long-term and short-term transfusions.

Table 4. Levels of serum ferritin, bilirubin, ALT, and AST in patients receiving long-term and short-term transfusions.

Variable	Long-term (n=21) Mean±SD	Short-term (n=29) Mean±SD	Statistic	p-value^a
Deferiprone (n=50)
Ferritin (ng/dL)	4864.65±2957.53	3125.49±1394.99	-2.776	0.008*
Total bilirubin (mg/dL)	1.52±0.64	1.3976±0.66	-0.630	0.532
Indirect bilirubin (mg/dL)	0.92±0.81	0.92±0.47	-0.009	0.993
Direct bilirubin (mg/dL)	0.59±0.42	0.48±0.28	259.000	0.371^b
ALT (IU/L)	45.67±29.19	48.31±30.24	274.500	0.555^b
AST (IU/L)	53.90±59.12	44.55±47.76	273.500	0.542^b
Deferasirox (n=40)
Ferritin (ng/dL)	4066.06±2959.85	4017.27±1941.73	183.50	0.668^b
Total bilirubin (mg/dL)	2.72±1.24	1.53±0.60	66.50	<0.001^b *
Indirect bilirubin (mg/dL)	1.98±1.20	0.95±0.43	62.50	<0.001^b *
Direct bilirubin (mg/dL)	0.75±0.47	0.56±0.41	110.50	0.015^b *
ALT (IU/L)	65.76±37.45	56.74±32.34	161.00	0.307^b
AST (IU/L)	56.95±55.00	53.89±47.79	169.00	0.421^b

a Otherwise stated, p-value was obtained from independent t-test.

b Obtained from Mann-Whitney U test.

* Statistically significant at p<0.05.

Discussion

Increased ferritin levels in the sera of thalassemic patients are expected since they have ineffective erythropoiesis conditions, allowing hyperabsorption of dietary irons in the intestines. Multiple reports have suggested the effect of iron overload-associated liver abnormalities, indicated by the raised level of liver enzymes. Egyptian patients with β-thalassemia, aged 1.1 to 17 years old, had a mean serum ferritin level of 1367.52 ± 856.22 ng/mL, which exceeded the normal range in children (7–140 ng/mL).¹⁹ Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.²⁰ Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion. Elevated ferritin as an iron storage marker was reported to have a strong correlation with iron overload condition.²¹ Among 291 thalassemic children in Cipto Mangunkusumo Hospital, Indonesia, there was a predominance of mild, moderate, and severe degrees of iron overload (28.2%, 34.7%, and 27.8%, respectively).²²

Overaccumulation of iron in the liver could damage the organ following reactive oxygen species (ROS) formation through Haber-Weiss and Fenton reactions.²³ Ferric iron could be reduced to ferrous iron resulting in the formation of hydroxyl radicals which promotes DNA and protein damages, oxidation of amino acid side chains, and peroxidation of phospholipid.²⁴ In this present study, we found the abnormally high averaged values of serum AST and ALT (51.57±32.77 and 49.19±48.32, respectively), suggesting the presence of hepatic injury. The correlation tests revealed that serum AST and ALT levels are strongly influenced by ferritin, hence hepatoxicity of iron overload. Similarly, a study on 100 patients with β-thalassemia major reported the strong positive correlation between serum ferritin and AST or ALT.¹⁹ Based on the study with a slightly higher number of transfusion-dependent thalassemic patients (n=138), ferritin was also found to be positively correlated with liver enzymes (AST and ALT).¹⁷ Among patients with acute dengue fever, similar relationships among serum ferritin, AST, and ALT were also reported, where serum ferritin was proposed as an indicator for liver damage.¹⁸ In the light of this iron toxicity, it is of importance for thalassemic patients undergoing blood transfusion to receive iron chelating therapies.

Herein, we observed differences of total, indirect, and direct bilirubin and ALT levels between deferiprone and deferasirox groups. All the aforementioned biomarkers were statistically higher in the latter group. In the correlation test, we did not find a correlation between ferritin and bilirubin, indicating that increased bilirubin was not associated with the efficacy of the iron chelator. In previous studies, hepatoxicity of deferasirox has been reported.²⁵^–²⁷ In drug-induced hepatic injury, the drugs induce the detrimental immune modulations after attaching to the enzyme molecules.²⁸ The neo-antigens eventually initiate the immune response cascade which could result in cytotoxicity and apoptosis.²⁸ Nonetheless, the reactions are delayed and required multiple exposures. Another proposed mechanism of the deferasirox-induced hepatic injury is the blockage of salt transport proteins (cholestatic injury),²⁵^,²⁶ which is supported by the findings of higher bilirubin levels in this present study. However, a case report suggested mitochondrial injury as the most explaining mechanism of deferasirox-induced liver injury which is consistent with elevations of transaminases.²⁷

Our data indicated that the levels of serum total, indirect bilirubin, and direct bilirubin were significantly higher in patients treated with deferasirox than deferiprone. Deferasirox has three ligands that could bind one Fe atom to form a complex with two chelator molecules while deferiprone only has two ligands.¹² The hepatoxicity effect of deferasirox was found to be more potent in patients with long-term transfusion as compared to those with short-term transfusion. However, interestingly, deferasirox could maintain its iron chelating efficacy even though the patients have undergone blood transfusion for more than 7 years. In the case of deferiprone, serum ferritin was produced at a higher level in patients with long-term blood transfusion. This is an indication that deferiprone lost its efficacy as an iron chelating agent as the patient received more blood transfusion. Our findings are in agreement with a study that continually monitored the long-term efficacy of deferasirox, which appeared to be sustained for 3.5 years.²⁹ Deferasirox uniquely has a longer half-life and bioavailability in the plasma (lasting for 24 hours) than other iron chelating therapies.³⁰ It is worth noting that, among patients receiving short-term blood transfusion herein, lower ferritin was observed in the deferiprone group than in the deferasirox group. In previous studies, deferasirox had a lower rate of effectiveness.¹⁶^,³¹

Our study had some limitations. For example, we did not simultaneously assess the effects of deferasirox or deferiprone in the thalassemic patients. The number of patients recruited in the study was too few, limiting the results in terms of being clinically meaningful. Moreover, we did not measure iron overload in specific organs, which could give an important insight since the drugs’ efficacies are dependent on the targeted organ. Diagnosis using magnetic resonance imaging (MRI) or other definitive tools should be carried out to conclude the hepatic injury in the patients.

Conclusions

Patients with β-thalassemia major have a higher level of serum ferritin, which is strongly correlated with the elevations of serum ALT and AST levels, respectively. Deferasirox poses a higher risk of developing liver dysfunction than deferiprone, as suggested by increased levels of bilirubin and ALT. While deferiprone has reduced efficacy among patients managed with long-term blood transfusion, deferasirox could yield a similar efficacy regardless of the length of the chronic transfusion. These findings could be used as guidance for medical practitioners in determining the oral chelating therapies for iron-overload conditions among β-thalassemia major patients, by considering the net clinical benefits of each drug. Although a higher number of participants is required to obtain meaningful clinical conclusions, medical practitioners should be aware of the net clinical benefit of prescribing the oral chelators to transfusion-dependent β-thalassemia major patients.

Data availability

Underlying data

Figshare: ‘Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes’. DOI: https://doi.org/10.6084/m9.figshare.21564114.³²

This project contains the following underlying data:

‐ Master Data.xlsx. [Table containing the raw data of the study.]

Data are available under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0).

Acknowledgements

We would like to thank all the healthcare workers at the Dr. Zainoel Abidin Hospital who assisted in this study.

References

1. Kattamis A, Forni GL, Aydinok Y, et al.: Changing patterns in the epidemiology of β-thalassemia. Eur. J. Haematol. 2020; 105(6): 692–703. PubMed Abstract | Publisher Full Text | Free Full Text
2. Colah R, Gorakshakar A, Nadkarni A: Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders. Expert. Rev. Hematol. 2010; 3(1): 103–117. PubMed Abstract | Publisher Full Text
3. Savongsy O, Fucharoen S, Fucharoen G, et al.: Thalassemia and hemoglobinopathies in pregnant Lao women: carrier screening, prevalence and molecular basis. Ann. Hematol. 2008; 87(8): 647–654. PubMed Abstract | Publisher Full Text
4. Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022; 46(1): 39–44. PubMed Abstract | Publisher Full Text
5. Lee J-S, Im Cho S, Park SS, et al.: Molecular basis and diagnosis of thalassemia. Blood Res. 2021; 56(S1): S39–S43. Publisher Full Text
6. Taher AT, Saliba AN: Iron overload in thalassemia: different organs at different rates. Hematology 2014, the American Society of Hematology Education Program Book. 2017; 2017(1): 265–271.
7. Koohi F, Kazemi T, Miri-Moghaddam E: Cardiac complications and iron overload in beta thalassemia major patients – a systematic review and meta-analysis. Ann. Hematol. 2019; 98(6): 1323–1331. PubMed Abstract | Publisher Full Text
8. Ballas SK, Zeidan AM, Duong VH, et al.: The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. Am. J. Hematol. 2018; 93(7): 943–952. PubMed Abstract | Publisher Full Text
9. Turner M, Deshpande S, Chitnis M, et al.: A Global Systematic Literature Review on the Burden of Illness in Transfusion-Dependent β-Thalassemia. Blood. 2019; 134: 5786. Publisher Full Text
10. Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022; 46(1): 39–44. PubMed Abstract | Publisher Full Text
11. Husna N, Sanka I, Arif AA, et al.: Prevalence and distribution of thalassemia trait screening. J. Med. Sci. 2017; 49(3): 106–113.
12. Kontoghiorghes GJ, Eracleous E, Economides C, et al.: Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr. Med. Chem. 2005; 12(23): 2663–2681. PubMed Abstract | Publisher Full Text
13. Wahidiyat PA, Liauw F, Sekarsari D, et al.: Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017; 22(8): 501–507. PubMed Abstract | Publisher Full Text
14. Wahidiyat PA, Wijaya E, Soedjatmiko S, et al.: Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells Mol. Dis. 2019; 77: 67–71. PubMed Abstract | Publisher Full Text
15. Kontoghiorghe CN, Kontoghiorghes GJ: Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des. Devel. Ther. 2016; 10: 465.
16. Kolnagou A, Kleanthous M, Kontoghiorghes GJ: Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur. J. Haematol. 2010; 85(5): 430–438. PubMed Abstract | Publisher Full Text
17. Al-Moshary M, Imtiaz N, Al-Mussaed E, et al.: Clinical and biochemical assessment of liver function test and its correlation with serum ferritin levels in transfusion-dependent thalassemia patients. Cureus. 2020; 12(4). Publisher Full Text
18. Zhang X, Fei Y, He T, et al.: Correlation analysis between serum ferritin level and liver damage in acute stage of dengue fever. Chin. J. Hepatol. 2021; 29(3): 265–270. PubMed Abstract | Publisher Full Text
19. Abdelrahman AM, Embaby M, Elsayh K: Screening of liver disease in thalassemic children admitted in Assiut University Hospital. Journal of Current Medical Research and Practice. 2021 October 1, 2021; 6(4): 358–362.
20. Origa R, Galanello R, Ganz T, et al.: Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica. 2007; 92(5): 583–588. PubMed Abstract | Publisher Full Text
21. Porter JB, Cappellini MD, Kattamis A, et al.: Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br. J. Haematol. 2017; 176(2): 288–299. PubMed Abstract | Publisher Full Text | Free Full Text
22. Wahidiyat PA, Iskandar SD, Rahmartani LD, et al.: Liver iron overload and hepatic function in children with thalassemia major. Paediatr. Indones. 2018; 58(5): 233–237. Publisher Full Text
23. Thompson JW, Bruick RK: Protein degradation and iron homeostasis. Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res. 2012; 1823(9): 1484–1490. Publisher Full Text
24. Anderson ER, Shah YM: Iron homeostasis in the liver. Compr. Physiol. 2013; 3(1): 315–330. PubMed Abstract | Publisher Full Text
25. Cermanova J, Kadova Z, Dolezelova E, et al.: Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. Shock. 2014; 42(4): 372–379. Publisher Full Text
26. Menaker N, Halligan K, Shur N, et al.: Acute liver failure during deferasirox chelation: a toxicity worth considering. J. Pediatr. Hematol. Oncol. 2017; 39(3): 217–222. PubMed Abstract | Publisher Full Text
27. Aslam N, Mettu P, Marsano-Obando LS, et al.: Deferasirox induced liver injury in haemochromatosis. J. Coll. Physicians Surg. Pak. 2010; 20(8): 551–553. PubMed Abstract
28. Chen M, Suzuki A, Borlak J, et al.: Drug-induced liver injury: Interactions between drug properties and host factors. J. Hepatol. 2015; 63(2): 503–514. PubMed Abstract | Publisher Full Text
29. Cappellini MD: Long-term efficacy and safety of deferasirox. Blood Rev. 2008; 22: S35–S41. Publisher Full Text
30. Cappellini MD: Exjade (R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther. Clin. Risk Manag. 2007; 3(2): 291–299. PubMed Abstract | Publisher Full Text | Free Full Text
31. Neufeld EJ: Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006; 107(9): 3436–3441. PubMed Abstract | Publisher Full Text | Free Full Text
32. Yusuf S, Herdata HN, Edward ED, et al.: Underlying data for ‘Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes’.Publisher Full Text

Comments on this article Comments (0)

Version 2

VERSION 2 PUBLISHED 10 Feb 2023

Author details Author details

Heru Noviat Herdata
Roles: Formal Analysis, Investigation, Methodology, Resources, Validation, Writing – Review & Editing

Eka Destianti Edward
Roles: Data Curation, Formal Analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – Review & Editing

Khairunnisa Khairunnisa
Roles: Investigation, Resources, Supervision, Validation, Visualization, Writing – Review & Editing

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Article Versions (2)

version 2

Revised

Published: 19 Dec 2023, 12:154

https://doi.org/10.12688/f1000research.128810.2

version 1

Published: 10 Feb 2023, 12:154

https://doi.org/10.12688/f1000research.128810.1

© 2023 Yusuf S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download

Export To

metrics

	Views	Downloads
F1000Research	-	-
PubMed Central Data from PMC are received and updated monthly.	-	-

Citations

SEE MORE DETAILS

CITE

how to cite this article

Yusuf S, Herdata HN, Edward ED and Khairunnisa K. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]. F1000Research 2023, 12:154 (https://doi.org/10.12688/f1000research.128810.2)

NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.

track

receive updates on this article

Track an article to receive email alerts on any updates to this article.

Open Peer Review

Version 2

VERSION 2

PUBLISHED 19 Dec 2023

Revised

Views

Reviewer Report 03 Sep 2024

Pustika Amalia Wahidiyat, Department of Child Health, Division of Hematology-Oncology, Cipto Mangunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia

Approved

https://doi.org/10.5256/f1000research.160173.r231351

No further comments ... Continue reading

CITE

Report a concern

Respond or Comment

Version 1

VERSION 1

PUBLISHED 10 Feb 2023

Views

Reviewer Report 24 Nov 2023

Ahmed Yahya Dallal Bashi, Al-Noor University College, Mosul, Iraq

Approved

https://doi.org/10.5256/f1000research.141435.r208966

Concerning the article titled "Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes", the work is a reasonable study to compare between 2 oral chelating drugs (Ferriprox (deferiprone) and Exjade (Deferasirox)) and their action in decreasing the level of serum ferritin and their effects on serum transaminases and serum bilirubin and the correlation between serum ferritin and the mentioned parameters. In my opinion the work was well done, and only few notes are required to be revised as follows:

Method: The doses of the 2 drugs were not mentioned which are very important as different protocols of treatment use different daily drugs doses.
Under the title "serum parameters analysis" methods for the estimation of serum; ferritin, AST, and ALT were mentioned while method of estimation of serum bilirubin was not mentioned.
Results: The mean length of the patients that was measured in meters was written as "125.96±18.06". This is in cm and if a meter unit is required then it is 1.2596±0.1806. The same fault was repeated in table 1.
Discussion: "Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.17". Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion.
The authors used the scientific names of the drugs which are general names of the main constituent of the drug. I think they have to use the trade names of the drugs and in 2 brackets the constituents of the drugs as follows: Ferriprox (deferiprone) and Exjade (deferasirox).
Aim of the study was mentioned in the "background" only and have to be repeated in more details at the end of the "Introduction".

In addition, in aim of the study mentioned in the "Background" I suggest adding (on the liver) and substituting the word (toxicity) by (adverse effects) so it become (This study aimed to compare the performance and adverse effects of deferiprone and Deferasirox on the liver in β-thalassemia major patients).

In my opinion the authors went many times out of the scope of the aim of the study which leads to a relatively long article and can be summarized to fulfill the aim of the study.

Is the work clearly and accurately presented and does it cite the current literature?

Yes
Is the study design appropriate and is the work technically sound?

Yes
Are sufficient details of methods and analysis provided to allow replication by others?

Yes
If applicable, is the statistical analysis and its interpretation appropriate?

Yes
Are all the source data underlying the results available to ensure full reproducibility?

Yes
Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical Biochemistry with Special interest in Thalassemia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

CITE

Report a concern

Author Response 16 Jan 2024

Sulaiman Yusuf, Division of Gastroenterohepatology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia

16 Jan 2024

Author Response

Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

1. Method: The doses of the 2 drugs were not mentioned which are ... Continue reading Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

1. Method: The doses of the 2 drugs were not mentioned which are very important as different protocols of treatment use different daily drugs doses.
Response: The dosage of the iron chelation used in the study has been added in the article.

2. Under the title "serum parameters analysis" methods for the estimation of serum; ferritin, AST, and ALT were mentioned while method of estimation of serum bilirubin was not mentioned.
Response: The method used to measure the serum bilirubin has been added under the heading of "Serum parameters analysis". Thank you.

3. Results: The mean length of the patients that was measured in meters was written as "125.96±18.06". This is in cm and if a meter unit is required then it is 1.2596±0.1806. The same fault was repeated in table 1.
Response: Thank you for pointing this issue. The values are now have been changed to metre: 1.25±0.18.

4. Discussion: "Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.17". Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion.
Response: The text have been revised. Thank you.

5. The authors used the scientific names of the drugs which are general names of the main constituent of the drug. I think they have to use the trade names of the drugs and in 2 brackets the constituents of the drugs as follows: Ferriprox (deferiprone) and Exjade (deferasirox).
Response: Thank you for your suggestion. We have used the style “Ferriprox ® (iron chelation containing deferiprone) or Exjade ® (iron chelation containing deferasirox)” in Introduction (aim) and at the beginning of the Methods section. This is help authors to have detailed information of the drugs used. We avoid to write the name of trading names in all texts of the article since it might less appropriate. This might have perception that the study funded by the companies of the drug. In addition, we used one brand only for each of the drug in this study with is Ferriprox ® for deferiprone and Exjade ® for deferasirox.

6. Aim of the study was mentioned in the "background" only and have to be repeated in more details at the end of the "Introduction". In addition, in aim of the study mentioned in the "Background" I suggest adding (on the liver) and substituting the word (toxicity) by (adverse effects) so it become (This study aimed to compare the performance and adverse effects of deferiprone and Deferasirox on the liver in β-thalassemia major patients).
Response: Thank you for raising this issue. The aim has been revised in the introduction and located at the end of the Introduction. It is now: “The objective of the study was to compare the performance and adverse effects of two oral iron chelating drugs (i.e., deferiprone (Ferriprox) and deferasirox (Exjade)) on the liver in β-thalassemia major patients with chronic transfusion. The effect on the liver were assessed by measuring the levels of serum ferritin, transaminase (ALT), aspartate transaminase (AST), total bilirubin, indirect bilirubin and direct bilirubin among patients with β-thalassemia major and chronic transfusion. In addition, we performed a correlation test between serum ferritin with ALT, AST, and total bilirubin.

7. In my opinion the authors went many times out of the scope of the aim of the study which leads to a relatively long article and can be summarized to fulfill the aim of the study.
Response: Thank you for your suggestion. Since we have two main objectives: To compare the performance and adverse effects as well as to determine the correlation test between serum ferritin with ALT, AST, and total bilirubin; therefore, the article a quite long since we have to prepare the manuscript based on the aims of the study. Now the aims have been articulated clearly in the end of the Introduction.
Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

1. Method: The doses of the 2 drugs were not mentioned which are very important as different protocols of treatment use different daily drugs doses.
Response: The dosage of the iron chelation used in the study has been added in the article.

2. Under the title "serum parameters analysis" methods for the estimation of serum; ferritin, AST, and ALT were mentioned while method of estimation of serum bilirubin was not mentioned.
Response: The method used to measure the serum bilirubin has been added under the heading of "Serum parameters analysis". Thank you.

3. Results: The mean length of the patients that was measured in meters was written as "125.96±18.06". This is in cm and if a meter unit is required then it is 1.2596±0.1806. The same fault was repeated in table 1.
Response: Thank you for pointing this issue. The values are now have been changed to metre: 1.25±0.18.

4. Discussion: "Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.17". Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion.
Response: The text have been revised. Thank you.

5. The authors used the scientific names of the drugs which are general names of the main constituent of the drug. I think they have to use the trade names of the drugs and in 2 brackets the constituents of the drugs as follows: Ferriprox (deferiprone) and Exjade (deferasirox).
Response: Thank you for your suggestion. We have used the style “Ferriprox ® (iron chelation containing deferiprone) or Exjade ® (iron chelation containing deferasirox)” in Introduction (aim) and at the beginning of the Methods section. This is help authors to have detailed information of the drugs used. We avoid to write the name of trading names in all texts of the article since it might less appropriate. This might have perception that the study funded by the companies of the drug. In addition, we used one brand only for each of the drug in this study with is Ferriprox ® for deferiprone and Exjade ® for deferasirox.

6. Aim of the study was mentioned in the "background" only and have to be repeated in more details at the end of the "Introduction". In addition, in aim of the study mentioned in the "Background" I suggest adding (on the liver) and substituting the word (toxicity) by (adverse effects) so it become (This study aimed to compare the performance and adverse effects of deferiprone and Deferasirox on the liver in β-thalassemia major patients).
Response: Thank you for raising this issue. The aim has been revised in the introduction and located at the end of the Introduction. It is now: “The objective of the study was to compare the performance and adverse effects of two oral iron chelating drugs (i.e., deferiprone (Ferriprox) and deferasirox (Exjade)) on the liver in β-thalassemia major patients with chronic transfusion. The effect on the liver were assessed by measuring the levels of serum ferritin, transaminase (ALT), aspartate transaminase (AST), total bilirubin, indirect bilirubin and direct bilirubin among patients with β-thalassemia major and chronic transfusion. In addition, we performed a correlation test between serum ferritin with ALT, AST, and total bilirubin.

7. In my opinion the authors went many times out of the scope of the aim of the study which leads to a relatively long article and can be summarized to fulfill the aim of the study.
Response: Thank you for your suggestion. Since we have two main objectives: To compare the performance and adverse effects as well as to determine the correlation test between serum ferritin with ALT, AST, and total bilirubin; therefore, the article a quite long since we have to prepare the manuscript based on the aims of the study. Now the aims have been articulated clearly in the end of the Introduction.
Competing Interests: I have no conflict of interest. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 16 Jan 2024

Sulaiman Yusuf, Division of Gastroenterohepatology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia

16 Jan 2024

Author Response

Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

1. Method: The doses of the 2 drugs were not mentioned which are ... Continue reading Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

1. Method: The doses of the 2 drugs were not mentioned which are very important as different protocols of treatment use different daily drugs doses.
Response: The dosage of the iron chelation used in the study has been added in the article.

2. Under the title "serum parameters analysis" methods for the estimation of serum; ferritin, AST, and ALT were mentioned while method of estimation of serum bilirubin was not mentioned.
Response: The method used to measure the serum bilirubin has been added under the heading of "Serum parameters analysis". Thank you.

3. Results: The mean length of the patients that was measured in meters was written as "125.96±18.06". This is in cm and if a meter unit is required then it is 1.2596±0.1806. The same fault was repeated in table 1.
Response: Thank you for pointing this issue. The values are now have been changed to metre: 1.25±0.18.

4. Discussion: "Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.17". Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion.
Response: The text have been revised. Thank you.

5. The authors used the scientific names of the drugs which are general names of the main constituent of the drug. I think they have to use the trade names of the drugs and in 2 brackets the constituents of the drugs as follows: Ferriprox (deferiprone) and Exjade (deferasirox).
Response: Thank you for your suggestion. We have used the style “Ferriprox ® (iron chelation containing deferiprone) or Exjade ® (iron chelation containing deferasirox)” in Introduction (aim) and at the beginning of the Methods section. This is help authors to have detailed information of the drugs used. We avoid to write the name of trading names in all texts of the article since it might less appropriate. This might have perception that the study funded by the companies of the drug. In addition, we used one brand only for each of the drug in this study with is Ferriprox ® for deferiprone and Exjade ® for deferasirox.

6. Aim of the study was mentioned in the "background" only and have to be repeated in more details at the end of the "Introduction". In addition, in aim of the study mentioned in the "Background" I suggest adding (on the liver) and substituting the word (toxicity) by (adverse effects) so it become (This study aimed to compare the performance and adverse effects of deferiprone and Deferasirox on the liver in β-thalassemia major patients).
Response: Thank you for raising this issue. The aim has been revised in the introduction and located at the end of the Introduction. It is now: “The objective of the study was to compare the performance and adverse effects of two oral iron chelating drugs (i.e., deferiprone (Ferriprox) and deferasirox (Exjade)) on the liver in β-thalassemia major patients with chronic transfusion. The effect on the liver were assessed by measuring the levels of serum ferritin, transaminase (ALT), aspartate transaminase (AST), total bilirubin, indirect bilirubin and direct bilirubin among patients with β-thalassemia major and chronic transfusion. In addition, we performed a correlation test between serum ferritin with ALT, AST, and total bilirubin.

7. In my opinion the authors went many times out of the scope of the aim of the study which leads to a relatively long article and can be summarized to fulfill the aim of the study.
Response: Thank you for your suggestion. Since we have two main objectives: To compare the performance and adverse effects as well as to determine the correlation test between serum ferritin with ALT, AST, and total bilirubin; therefore, the article a quite long since we have to prepare the manuscript based on the aims of the study. Now the aims have been articulated clearly in the end of the Introduction.
Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

1. Method: The doses of the 2 drugs were not mentioned which are very important as different protocols of treatment use different daily drugs doses.
Response: The dosage of the iron chelation used in the study has been added in the article.

2. Under the title "serum parameters analysis" methods for the estimation of serum; ferritin, AST, and ALT were mentioned while method of estimation of serum bilirubin was not mentioned.
Response: The method used to measure the serum bilirubin has been added under the heading of "Serum parameters analysis". Thank you.

3. Results: The mean length of the patients that was measured in meters was written as "125.96±18.06". This is in cm and if a meter unit is required then it is 1.2596±0.1806. The same fault was repeated in table 1.
Response: Thank you for pointing this issue. The values are now have been changed to metre: 1.25±0.18.

4. Discussion: "Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.17". Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion.
Response: The text have been revised. Thank you.

5. The authors used the scientific names of the drugs which are general names of the main constituent of the drug. I think they have to use the trade names of the drugs and in 2 brackets the constituents of the drugs as follows: Ferriprox (deferiprone) and Exjade (deferasirox).
Response: Thank you for your suggestion. We have used the style “Ferriprox ® (iron chelation containing deferiprone) or Exjade ® (iron chelation containing deferasirox)” in Introduction (aim) and at the beginning of the Methods section. This is help authors to have detailed information of the drugs used. We avoid to write the name of trading names in all texts of the article since it might less appropriate. This might have perception that the study funded by the companies of the drug. In addition, we used one brand only for each of the drug in this study with is Ferriprox ® for deferiprone and Exjade ® for deferasirox.

6. Aim of the study was mentioned in the "background" only and have to be repeated in more details at the end of the "Introduction". In addition, in aim of the study mentioned in the "Background" I suggest adding (on the liver) and substituting the word (toxicity) by (adverse effects) so it become (This study aimed to compare the performance and adverse effects of deferiprone and Deferasirox on the liver in β-thalassemia major patients).
Response: Thank you for raising this issue. The aim has been revised in the introduction and located at the end of the Introduction. It is now: “The objective of the study was to compare the performance and adverse effects of two oral iron chelating drugs (i.e., deferiprone (Ferriprox) and deferasirox (Exjade)) on the liver in β-thalassemia major patients with chronic transfusion. The effect on the liver were assessed by measuring the levels of serum ferritin, transaminase (ALT), aspartate transaminase (AST), total bilirubin, indirect bilirubin and direct bilirubin among patients with β-thalassemia major and chronic transfusion. In addition, we performed a correlation test between serum ferritin with ALT, AST, and total bilirubin.

7. In my opinion the authors went many times out of the scope of the aim of the study which leads to a relatively long article and can be summarized to fulfill the aim of the study.
Response: Thank you for your suggestion. Since we have two main objectives: To compare the performance and adverse effects as well as to determine the correlation test between serum ferritin with ALT, AST, and total bilirubin; therefore, the article a quite long since we have to prepare the manuscript based on the aims of the study. Now the aims have been articulated clearly in the end of the Introduction.
Competing Interests: I have no conflict of interest. Close
Report a concern

Views

Reviewer Report 06 Mar 2023

Pustika Amalia Wahidiyat, Department of Child Health, Division of Hematology-Oncology, Cipto Mangunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia

Approved with Reservations

https://doi.org/10.5256/f1000research.141435.r164926

This study is a prospective study comparing two oral iron chelating drugs, deferiprone and deferasirox, in reducing iron overload and its effects on serum transaminase and bilirubin levels. This study also evaluated the correlation between serum ferritin with ALT, AST, ... Continue reading

Since similar studies with greater number of subjects have been established. Please provide the novelty of this study.
Please provide data from Indonesia

Methods

Please provide data about the dosage of iron chelation used in this study.
Considering most of the patients with transfusion dependent thalassemia had organomegaly, please re-assessed the nutritional status based on the mid-upper arm circumference.
Since ferritin is easily affected by inflammatory status, please provide the technique to exclude the possibility of inflammatory state

Results

Please provide the analysis data between dosage used and the dependent variables
Please revised the height data in “metre” unit

Discussion

Please provide more discussion about the results findings, especially the difference between the two types of drugs.

Is the work clearly and accurately presented and does it cite the current literature?

Yes
Is the study design appropriate and is the work technically sound?

Partly
Are sufficient details of methods and analysis provided to allow replication by others?

Partly
If applicable, is the statistical analysis and its interpretation appropriate?

Yes
Are all the source data underlying the results available to ensure full reproducibility?

Yes
Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Thalassemia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

CITE

Report a concern

Author Response 16 Jan 2024

Sulaiman Yusuf, Division of Gastroenterohepatology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia

16 Jan 2024

Author Response

Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

Introduction
1. Since similar studies with greater number of subjects have been established. Please ... Continue reading Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

Introduction
1. Since similar studies with greater number of subjects have been established. Please provide the novelty of this study.
Response: Thank you. We have added the novelty of the study. Mainly since most of the studies in Indonesia are from Java; studies outside of the Java is important to see of any differences.

2. Please provide data from Indonesia
Response: The data of Thalassemia from Indonesia has been added in the text. The references have been adeed: Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022;46(1):39-44. doi: 10.1080/03630269.2021.2023565.
Wahidiyat PA, Liauw F, Sekarsari D, et al.: Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017;22(8):501-507. doi: 10.1080/10245332.2017.1292614
Wahidiyat PA, Wijaya E, Soedjatmiko S, et al.: Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells Mol Dis 2019;77:67-71. doi: 10.1016/j.bcmd.2019.03.007.

Methods
3. Please provide data about the dosage of iron chelation used in this study.
Response: The dosage of the iron chelation used in the study has been added in the article.

4. Considering most of the patients with transfusion dependent thalassemia had organomegaly, please re-assessed the nutritional status based on the mid-upper arm circumference.
Response: Thank you for your suggestion; however, not all patients have the mid-upper arm circumference data in our database.

5. Since ferritin is easily affected by inflammatory status, please provide the technique to exclude the possibility of inflammatory state.
Response: Thank you for your question. In all patients, the level of ferritin was measured only the patients had no infection (assessed through physically and laboratory tests including routine lab, C-reactive protein level and procalcitonin) and had no autoimmune diseases.

Results
6. Please provide the analysis data between dosage used and the dependent variables.
Response: Thank you for your suggestion. Unfortunately, all the patients in our study were treated with the same dose of iron chelation drugs (deferiprone with dose 75 mg/kg body weight each day and deferasirox with dose of 20 mg/kg body weight each day for single dose).

7. Please revised the height data in “metre” unit
Response: The unit of the height has been changed to unit metre.

Discussion
8. Please provide more discussion about the results findings, especially the difference between the two types of drugs.
Response: More discussion has been added in particular the difference between the two types of oral chelating drugs (deferiprone and deferasirox) used in this study.
Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

Introduction
1. Since similar studies with greater number of subjects have been established. Please provide the novelty of this study.
Response: Thank you. We have added the novelty of the study. Mainly since most of the studies in Indonesia are from Java; studies outside of the Java is important to see of any differences.

2. Please provide data from Indonesia
Response: The data of Thalassemia from Indonesia has been added in the text. The references have been adeed: Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022;46(1):39-44. doi: 10.1080/03630269.2021.2023565.
Wahidiyat PA, Liauw F, Sekarsari D, et al.: Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017;22(8):501-507. doi: 10.1080/10245332.2017.1292614
Wahidiyat PA, Wijaya E, Soedjatmiko S, et al.: Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells Mol Dis 2019;77:67-71. doi: 10.1016/j.bcmd.2019.03.007.

Methods
3. Please provide data about the dosage of iron chelation used in this study.
Response: The dosage of the iron chelation used in the study has been added in the article.

4. Considering most of the patients with transfusion dependent thalassemia had organomegaly, please re-assessed the nutritional status based on the mid-upper arm circumference.
Response: Thank you for your suggestion; however, not all patients have the mid-upper arm circumference data in our database.

5. Since ferritin is easily affected by inflammatory status, please provide the technique to exclude the possibility of inflammatory state.
Response: Thank you for your question. In all patients, the level of ferritin was measured only the patients had no infection (assessed through physically and laboratory tests including routine lab, C-reactive protein level and procalcitonin) and had no autoimmune diseases.

Results
6. Please provide the analysis data between dosage used and the dependent variables.
Response: Thank you for your suggestion. Unfortunately, all the patients in our study were treated with the same dose of iron chelation drugs (deferiprone with dose 75 mg/kg body weight each day and deferasirox with dose of 20 mg/kg body weight each day for single dose).

7. Please revised the height data in “metre” unit
Response: The unit of the height has been changed to unit metre.

Discussion
8. Please provide more discussion about the results findings, especially the difference between the two types of drugs.
Response: More discussion has been added in particular the difference between the two types of oral chelating drugs (deferiprone and deferasirox) used in this study.
Competing Interests: I do not have conflict of interest Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 16 Jan 2024

Sulaiman Yusuf, Division of Gastroenterohepatology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia

16 Jan 2024

Author Response

Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

Introduction
1. Since similar studies with greater number of subjects have been established. Please ... Continue reading Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

Introduction
1. Since similar studies with greater number of subjects have been established. Please provide the novelty of this study.
Response: Thank you. We have added the novelty of the study. Mainly since most of the studies in Indonesia are from Java; studies outside of the Java is important to see of any differences.

2. Please provide data from Indonesia
Response: The data of Thalassemia from Indonesia has been added in the text. The references have been adeed: Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022;46(1):39-44. doi: 10.1080/03630269.2021.2023565.
Wahidiyat PA, Liauw F, Sekarsari D, et al.: Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017;22(8):501-507. doi: 10.1080/10245332.2017.1292614
Wahidiyat PA, Wijaya E, Soedjatmiko S, et al.: Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells Mol Dis 2019;77:67-71. doi: 10.1016/j.bcmd.2019.03.007.

Methods
3. Please provide data about the dosage of iron chelation used in this study.
Response: The dosage of the iron chelation used in the study has been added in the article.

4. Considering most of the patients with transfusion dependent thalassemia had organomegaly, please re-assessed the nutritional status based on the mid-upper arm circumference.
Response: Thank you for your suggestion; however, not all patients have the mid-upper arm circumference data in our database.

5. Since ferritin is easily affected by inflammatory status, please provide the technique to exclude the possibility of inflammatory state.
Response: Thank you for your question. In all patients, the level of ferritin was measured only the patients had no infection (assessed through physically and laboratory tests including routine lab, C-reactive protein level and procalcitonin) and had no autoimmune diseases.

Results
6. Please provide the analysis data between dosage used and the dependent variables.
Response: Thank you for your suggestion. Unfortunately, all the patients in our study were treated with the same dose of iron chelation drugs (deferiprone with dose 75 mg/kg body weight each day and deferasirox with dose of 20 mg/kg body weight each day for single dose).

7. Please revised the height data in “metre” unit
Response: The unit of the height has been changed to unit metre.

Discussion
8. Please provide more discussion about the results findings, especially the difference between the two types of drugs.
Response: More discussion has been added in particular the difference between the two types of oral chelating drugs (deferiprone and deferasirox) used in this study.
Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

Introduction
1. Since similar studies with greater number of subjects have been established. Please provide the novelty of this study.
Response: Thank you. We have added the novelty of the study. Mainly since most of the studies in Indonesia are from Java; studies outside of the Java is important to see of any differences.

2. Please provide data from Indonesia
Response: The data of Thalassemia from Indonesia has been added in the text. The references have been adeed: Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022;46(1):39-44. doi: 10.1080/03630269.2021.2023565.
Wahidiyat PA, Liauw F, Sekarsari D, et al.: Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017;22(8):501-507. doi: 10.1080/10245332.2017.1292614
Wahidiyat PA, Wijaya E, Soedjatmiko S, et al.: Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells Mol Dis 2019;77:67-71. doi: 10.1016/j.bcmd.2019.03.007.

Methods
3. Please provide data about the dosage of iron chelation used in this study.
Response: The dosage of the iron chelation used in the study has been added in the article.

4. Considering most of the patients with transfusion dependent thalassemia had organomegaly, please re-assessed the nutritional status based on the mid-upper arm circumference.
Response: Thank you for your suggestion; however, not all patients have the mid-upper arm circumference data in our database.

5. Since ferritin is easily affected by inflammatory status, please provide the technique to exclude the possibility of inflammatory state.
Response: Thank you for your question. In all patients, the level of ferritin was measured only the patients had no infection (assessed through physically and laboratory tests including routine lab, C-reactive protein level and procalcitonin) and had no autoimmune diseases.

Results
6. Please provide the analysis data between dosage used and the dependent variables.
Response: Thank you for your suggestion. Unfortunately, all the patients in our study were treated with the same dose of iron chelation drugs (deferiprone with dose 75 mg/kg body weight each day and deferasirox with dose of 20 mg/kg body weight each day for single dose).

7. Please revised the height data in “metre” unit
Response: The unit of the height has been changed to unit metre.

Discussion
8. Please provide more discussion about the results findings, especially the difference between the two types of drugs.
Response: More discussion has been added in particular the difference between the two types of oral chelating drugs (deferiprone and deferasirox) used in this study.
Competing Interests: I do not have conflict of interest Close
Report a concern

Comments on this article Comments (0)

Version 2

VERSION 2 PUBLISHED 10 Feb 2023

Open Peer Review

Reviewer Status

Reviewer Reports

	Invited Reviewers
	1	2
Version 2 (revision) 19 Dec 23	read
Version 1 10 Feb 23	read	read

Pustika Amalia Wahidiyat, University of Indonesia, Jakarta, Indonesia
Ahmed Yahya Dallal Bashi, Al-Noor University College, Mosul, Iraq

Comments on this article

All Comments(0)

Add a comment

Browse by related subjects

Back to all reports

Reviewer Report

2 Views

03 Sep 2024 | for Version 2

Pustika Amalia Wahidiyat, Department of Child Health, Division of Hematology-Oncology, Cipto Mangunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia

2 Views Cite this report Responses(0)

Approved

No further comments for this article

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Thalassemia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Respond to this report

Responses (0)

Back to all reports

Reviewer Report

12 Views

24 Nov 2023 | for Version 1

Ahmed Yahya Dallal Bashi, Al-Noor University College, Mosul, Iraq

12 Views Cite this report Responses(1)

Approved

Method: The doses of the 2 drugs were not mentioned which are very important as different protocols of treatment use different daily drugs doses.
Under the title "serum parameters analysis" methods for the estimation of serum; ferritin, AST, and ALT were mentioned while method of estimation of serum bilirubin was not mentioned.
Results: The mean length of the patients that was measured in meters was written as "125.96±18.06". This is in cm and if a meter unit is required then it is 1.2596±0.1806. The same fault was repeated in table 1.
Discussion: "Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.17". Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion.
The authors used the scientific names of the drugs which are general names of the main constituent of the drug. I think they have to use the trade names of the drugs and in 2 brackets the constituents of the drugs as follows: Ferriprox (deferiprone) and Exjade (deferasirox).
Aim of the study was mentioned in the "background" only and have to be repeated in more details at the end of the "Introduction".

In my opinion the authors went many times out of the scope of the aim of the study which leads to a relatively long article and can be summarized to fulfill the aim of the study.

Is the work clearly and accurately presented and does it cite the current literature?

Yes
Is the study design appropriate and is the work technically sound?

Yes
Are sufficient details of methods and analysis provided to allow replication by others?

Yes
If applicable, is the statistical analysis and its interpretation appropriate?

Yes
Are all the source data underlying the results available to ensure full reproducibility?

Yes
Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Clinical Biochemistry with Special interest in Thalassemia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Respond to this report

Responses (1)

Author Response

16 Jan 2024

Sulaiman Yusuf, Division of Gastroenterohepatology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia

Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

1. Method: The doses of the 2 drugs were not mentioned which are very important as different protocols of treatment use different daily drugs doses.
Response: The dosage of the iron chelation used in the study has been added in the article.

2. Under the title "serum parameters analysis" methods for the estimation of serum; ferritin, AST, and ALT were mentioned while method of estimation of serum bilirubin was not mentioned.
Response: The method used to measure the serum bilirubin has been added under the heading of "Serum parameters analysis". Thank you.

3. Results: The mean length of the patients that was measured in meters was written as "125.96±18.06". This is in cm and if a meter unit is required then it is 1.2596±0.1806. The same fault was repeated in table 1.
Response: Thank you for pointing this issue. The values are now have been changed to metre: 1.25±0.18.

4. Discussion: "Following the blood transfusion, irons are retained in the macrophages due to the increased hepcidin, hence elevation in serum ferritin.17". Hepcidin production is suppressed due to erythropoietic activity which allows increased absorption of dietary iron in addition to the iron obtained from blood transfusion.
Response: The text have been revised. Thank you.

5. The authors used the scientific names of the drugs which are general names of the main constituent of the drug. I think they have to use the trade names of the drugs and in 2 brackets the constituents of the drugs as follows: Ferriprox (deferiprone) and Exjade (deferasirox).
Response: Thank you for your suggestion. We have used the style “Ferriprox ® (iron chelation containing deferiprone) or Exjade ® (iron chelation containing deferasirox)” in Introduction (aim) and at the beginning of the Methods section. This is help authors to have detailed information of the drugs used. We avoid to write the name of trading names in all texts of the article since it might less appropriate. This might have perception that the study funded by the companies of the drug. In addition, we used one brand only for each of the drug in this study with is Ferriprox ® for deferiprone and Exjade ® for deferasirox.

6. Aim of the study was mentioned in the "background" only and have to be repeated in more details at the end of the "Introduction". In addition, in aim of the study mentioned in the "Background" I suggest adding (on the liver) and substituting the word (toxicity) by (adverse effects) so it become (This study aimed to compare the performance and adverse effects of deferiprone and Deferasirox on the liver in β-thalassemia major patients).
Response: Thank you for raising this issue. The aim has been revised in the introduction and located at the end of the Introduction. It is now: “The objective of the study was to compare the performance and adverse effects of two oral iron chelating drugs (i.e., deferiprone (Ferriprox) and deferasirox (Exjade)) on the liver in β-thalassemia major patients with chronic transfusion. The effect on the liver were assessed by measuring the levels of serum ferritin, transaminase (ALT), aspartate transaminase (AST), total bilirubin, indirect bilirubin and direct bilirubin among patients with β-thalassemia major and chronic transfusion. In addition, we performed a correlation test between serum ferritin with ALT, AST, and total bilirubin.

7. In my opinion the authors went many times out of the scope of the aim of the study which leads to a relatively long article and can be summarized to fulfill the aim of the study.
Response: Thank you for your suggestion. Since we have two main objectives: To compare the performance and adverse effects as well as to determine the correlation test between serum ferritin with ALT, AST, and total bilirubin; therefore, the article a quite long since we have to prepare the manuscript based on the aims of the study. Now the aims have been articulated clearly in the end of the Introduction.

View more View less

Competing Interests

I have no conflict of interest.

Back to all reports

Reviewer Report

32 Views

06 Mar 2023 | for Version 1

Pustika Amalia Wahidiyat, Department of Child Health, Division of Hematology-Oncology, Cipto Mangunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia

32 Views Cite this report Responses(1)

Approved With Reservations

Since similar studies with greater number of subjects have been established. Please provide the novelty of this study.
Please provide data from Indonesia

Methods

Please provide data about the dosage of iron chelation used in this study.
Considering most of the patients with transfusion dependent thalassemia had organomegaly, please re-assessed the nutritional status based on the mid-upper arm circumference.
Since ferritin is easily affected by inflammatory status, please provide the technique to exclude the possibility of inflammatory state

Results

Please provide the analysis data between dosage used and the dependent variables
Please revised the height data in “metre” unit

Discussion

Please provide more discussion about the results findings, especially the difference between the two types of drugs.

Is the work clearly and accurately presented and does it cite the current literature?

Yes
Is the study design appropriate and is the work technically sound?

Partly
Are sufficient details of methods and analysis provided to allow replication by others?

Partly
If applicable, is the statistical analysis and its interpretation appropriate?

Yes
Are all the source data underlying the results available to ensure full reproducibility?

Yes
Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Thalassemia

Respond to this report

Responses (1)

Author Response

16 Jan 2024

Sulaiman Yusuf, Division of Gastroenterohepatology, Department of Pediatrics, School of Medicine, Universitas Syiah Kuala - Dr. Zainoel Abidin Hospital, Banda Aceh, 23111, Indonesia

Dear Reviewer,

Thank you for your important suggestions. Here are our responses for each comments.

Introduction
1. Since similar studies with greater number of subjects have been established. Please provide the novelty of this study.
Response: Thank you. We have added the novelty of the study. Mainly since most of the studies in Indonesia are from Java; studies outside of the Java is important to see of any differences.

2. Please provide data from Indonesia
Response: The data of Thalassemia from Indonesia has been added in the text. The references have been adeed: Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022;46(1):39-44. doi: 10.1080/03630269.2021.2023565.
Wahidiyat PA, Liauw F, Sekarsari D, et al.: Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017;22(8):501-507. doi: 10.1080/10245332.2017.1292614
Wahidiyat PA, Wijaya E, Soedjatmiko S, et al.: Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells Mol Dis 2019;77:67-71. doi: 10.1016/j.bcmd.2019.03.007.

Methods
3. Please provide data about the dosage of iron chelation used in this study.
Response: The dosage of the iron chelation used in the study has been added in the article.

4. Considering most of the patients with transfusion dependent thalassemia had organomegaly, please re-assessed the nutritional status based on the mid-upper arm circumference.
Response: Thank you for your suggestion; however, not all patients have the mid-upper arm circumference data in our database.

5. Since ferritin is easily affected by inflammatory status, please provide the technique to exclude the possibility of inflammatory state.
Response: Thank you for your question. In all patients, the level of ferritin was measured only the patients had no infection (assessed through physically and laboratory tests including routine lab, C-reactive protein level and procalcitonin) and had no autoimmune diseases.

Results
6. Please provide the analysis data between dosage used and the dependent variables.
Response: Thank you for your suggestion. Unfortunately, all the patients in our study were treated with the same dose of iron chelation drugs (deferiprone with dose 75 mg/kg body weight each day and deferasirox with dose of 20 mg/kg body weight each day for single dose).

7. Please revised the height data in “metre” unit
Response: The unit of the height has been changed to unit metre.

Discussion
8. Please provide more discussion about the results findings, especially the difference between the two types of drugs.
Response: More discussion has been added in particular the difference between the two types of oral chelating drugs (deferiprone and deferasirox) used in this study.

View more View less

Competing Interests

I do not have conflict of interest

Alongside their report, reviewers assign a status to the article:

Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested

Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.

Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions

[1] 1. Kattamis A, Forni GL, Aydinok Y, et al.: Changing patterns in the epidemiology of β-thalassemia. Eur. J. Haematol. 2020; 105(6): 692–703. PubMed Abstract | Publisher Full Text | Free Full Text

[2] 2. Colah R, Gorakshakar A, Nadkarni A: Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders. Expert. Rev. Hematol. 2010; 3(1): 103–117. PubMed Abstract | Publisher Full Text

[3] 3. Savongsy O, Fucharoen S, Fucharoen G, et al.: Thalassemia and hemoglobinopathies in pregnant Lao women: carrier screening, prevalence and molecular basis. Ann. Hematol. 2008; 87(8): 647–654. PubMed Abstract | Publisher Full Text

[4] 4. Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022; 46(1): 39–44. PubMed Abstract | Publisher Full Text

[5] 5. Lee J-S, Im Cho S, Park SS, et al.: Molecular basis and diagnosis of thalassemia. Blood Res. 2021; 56(S1): S39–S43. Publisher Full Text

[6] 6. Taher AT, Saliba AN: Iron overload in thalassemia: different organs at different rates. Hematology 2014, the American Society of Hematology Education Program Book. 2017; 2017(1): 265–271.

[7] 7. Koohi F, Kazemi T, Miri-Moghaddam E: Cardiac complications and iron overload in beta thalassemia major patients – a systematic review and meta-analysis. Ann. Hematol. 2019; 98(6): 1323–1331. PubMed Abstract | Publisher Full Text

[8] 8. Ballas SK, Zeidan AM, Duong VH, et al.: The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. Am. J. Hematol. 2018; 93(7): 943–952. PubMed Abstract | Publisher Full Text

[9] 9. Turner M, Deshpande S, Chitnis M, et al.: A Global Systematic Literature Review on the Burden of Illness in Transfusion-Dependent β-Thalassemia. Blood. 2019; 134: 5786. Publisher Full Text

[10] 10. Wahidiyat PA, Sari TT, Rahmartani LD, et al.: Thalassemia in Indonesia. Hemoglobin. 2022; 46(1): 39–44. PubMed Abstract | Publisher Full Text

[11] 11. Husna N, Sanka I, Arif AA, et al.: Prevalence and distribution of thalassemia trait screening. J. Med. Sci. 2017; 49(3): 106–113.

[12] 12. Kontoghiorghes GJ, Eracleous E, Economides C, et al.: Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr. Med. Chem. 2005; 12(23): 2663–2681. PubMed Abstract | Publisher Full Text

[13] 13. Wahidiyat PA, Liauw F, Sekarsari D, et al.: Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017; 22(8): 501–507. PubMed Abstract | Publisher Full Text

[14] 14. Wahidiyat PA, Wijaya E, Soedjatmiko S, et al.: Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major. Blood Cells Mol. Dis. 2019; 77: 67–71. PubMed Abstract | Publisher Full Text

[15] 15. Kontoghiorghe CN, Kontoghiorghes GJ: Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des. Devel. Ther. 2016; 10: 465.

[16] 16. Kolnagou A, Kleanthous M, Kontoghiorghes GJ: Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur. J. Haematol. 2010; 85(5): 430–438. PubMed Abstract | Publisher Full Text

[17] 17. Al-Moshary M, Imtiaz N, Al-Mussaed E, et al.: Clinical and biochemical assessment of liver function test and its correlation with serum ferritin levels in transfusion-dependent thalassemia patients. Cureus. 2020; 12(4). Publisher Full Text

[18] 18. Zhang X, Fei Y, He T, et al.: Correlation analysis between serum ferritin level and liver damage in acute stage of dengue fever. Chin. J. Hepatol. 2021; 29(3): 265–270. PubMed Abstract | Publisher Full Text

[19] 19. Abdelrahman AM, Embaby M, Elsayh K: Screening of liver disease in thalassemic children admitted in Assiut University Hospital. Journal of Current Medical Research and Practice. 2021 October 1, 2021; 6(4): 358–362.

[20] 20. Origa R, Galanello R, Ganz T, et al.: Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica. 2007; 92(5): 583–588. PubMed Abstract | Publisher Full Text

[21] 21. Porter JB, Cappellini MD, Kattamis A, et al.: Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br. J. Haematol. 2017; 176(2): 288–299. PubMed Abstract | Publisher Full Text | Free Full Text

[22] 22. Wahidiyat PA, Iskandar SD, Rahmartani LD, et al.: Liver iron overload and hepatic function in children with thalassemia major. Paediatr. Indones. 2018; 58(5): 233–237. Publisher Full Text

[23] 23. Thompson JW, Bruick RK: Protein degradation and iron homeostasis. Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res. 2012; 1823(9): 1484–1490. Publisher Full Text

[24] 24. Anderson ER, Shah YM: Iron homeostasis in the liver. Compr. Physiol. 2013; 3(1): 315–330. PubMed Abstract | Publisher Full Text

[25] 25. Cermanova J, Kadova Z, Dolezelova E, et al.: Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. Shock. 2014; 42(4): 372–379. Publisher Full Text

[26] 26. Menaker N, Halligan K, Shur N, et al.: Acute liver failure during deferasirox chelation: a toxicity worth considering. J. Pediatr. Hematol. Oncol. 2017; 39(3): 217–222. PubMed Abstract | Publisher Full Text

[27] 27. Aslam N, Mettu P, Marsano-Obando LS, et al.: Deferasirox induced liver injury in haemochromatosis. J. Coll. Physicians Surg. Pak. 2010; 20(8): 551–553. PubMed Abstract

[28] 28. Chen M, Suzuki A, Borlak J, et al.: Drug-induced liver injury: Interactions between drug properties and host factors. J. Hepatol. 2015; 63(2): 503–514. PubMed Abstract | Publisher Full Text

[29] 29. Cappellini MD: Long-term efficacy and safety of deferasirox. Blood Rev. 2008; 22: S35–S41. Publisher Full Text

[30] 30. Cappellini MD: Exjade (R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther. Clin. Risk Manag. 2007; 3(2): 291–299. PubMed Abstract | Publisher Full Text | Free Full Text

[31] 31. Neufeld EJ: Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006; 107(9): 3436–3441. PubMed Abstract | Publisher Full Text | Free Full Text

[32] 32. Yusuf S, Herdata HN, Edward ED, et al.: Underlying data for ‘Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes’.Publisher Full Text

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes

Abstract

Background

Methods

Results

Conclusions

Keywords

Revised Amendments from Version 1

Introduction

Methods

Study design

Patient recruitment

Data collection

Serum parameters analysis

Statistical analysis

Results

Characteristics of patients

Table 1. Characteristics of the patients (n=102).

Correlations between serum ferritin and liver enzymes

Table 2. Correlation between ferritin and ALT, AST, or total bilirubin (n=102).

Comparisons between deferiprone and deferasirox

Table 3. Comparisons between deferiprone and deferasirox based on levels of serum ferritin, bilirubin, ALT, and AST (n=90).

Table 4. Levels of serum ferritin, bilirubin, ALT, and AST in patients receiving long-term and short-term transfusions.

Discussion

Conclusions

Data availability

Underlying data

Acknowledgements

References

Comments on this article Comments (0)

Open Peer Review

Comments on this article Comments (0)

Open Peer Review

Reviewer Status

Reviewer Reports

Comments on this article

Browse by related subjects

Competing Interests Policy

Stay Updated